919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
650 473 7700
https://www.geron.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 141
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. John A. Scarlett M.D. | Chairman of the Board, President & CEO | 1,36M | S.O. | 1951 |
Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO | 827,01k | S.O. | 1964 |
Mr. Scott Samuels | Executive VP, Chief Legal Officer & Corporate Secretary | 485,32k | S.O. | S.O. |
Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | S.O. | S.O. | S.O. |
Ms. Shannon Odam | Senior VP & Chief People Officer | S.O. | S.O. | 1975 |
Ms. Melissa A. Kelly Behrs | Executive VP of Business Operations & Chief Alliance Officer | 753,22k | S.O. | 1964 |
Mr. Edward E. Koval | Executive VP & Chief Business Officer | S.O. | S.O. | 1962 |
Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer | S.O. | S.O. | 1983 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
L’ISS Governance QualityScore de Geron Corporation en date du 1 avril 2024 est 7. Les scores principaux sont Audit : 8; Société : 5; Droits des actionnaires : 9; Compensation : 6.